About Cullinan Therapeutics, Inc.
https://cullinantherapeutics.comCullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
CEO
Nadim Ahmed
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 120
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BIOIMPACT CAPITAL LLC
Shares:7.65M
Value:$83.14M
LYNX1 CAPITAL MANAGEMENT LP
Shares:5.77M
Value:$62.68M
BVF INC/IL
Shares:5.75M
Value:$62.51M
Summary
Showing Top 3 of 160
About Cullinan Therapeutics, Inc.
https://cullinantherapeutics.comCullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $55.59M ▼ | $-50.61M ▲ | 0% | $-0.86 ▲ | $-50.53M ▲ |
| Q2-2025 | $0 | $75.8M ▲ | $-70.06M ▼ | 0% | $-1.19 ▼ | $-75.72M ▼ |
| Q1-2025 | $0 | $55M ▼ | $-48.5M ▼ | 0% | $-0.82 ▼ | $-54.92M ▲ |
| Q4-2024 | $0 | $55.05M ▲ | $-47.65M ▼ | 0% | $-0.81 ▼ | $-54.97M ▼ |
| Q3-2024 | $0 | $48.85M | $-40.56M | 0% | $-0.7 | $-48.78M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $332.6M ▲ | $484.13M ▼ | $32.76M ▲ | $451.37M ▼ |
| Q2-2025 | $265.48M ▼ | $520.33M ▼ | $28.18M ▲ | $492.15M ▼ |
| Q1-2025 | $303.83M ▼ | $579.68M ▼ | $27.84M ▼ | $551.84M ▼ |
| Q4-2024 | $398.98M ▼ | $621.82M ▼ | $31.5M ▲ | $590.33M ▼ |
| Q3-2024 | $578.08M | $653.25M | $25.39M | $627.86M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-50.61M ▲ | $-36.88M ▲ | $67.39M ▲ | $0 ▼ | $30.52M ▲ | $0 ▲ |
| Q2-2025 | $-70.06M ▼ | $-57.61M ▼ | $53.4M ▲ | $373K ▲ | $-3.83M ▲ | $-57.61M ▼ |
| Q1-2025 | $-48.5M ▼ | $-43.16M ▼ | $36.8M ▲ | $0 ▼ | $-6.35M ▲ | $-43.16M ▼ |
| Q4-2024 | $-47.65M ▼ | $-36.63M ▼ | $15.96M ▼ | $1.58M ▲ | $-19.08M ▼ | $-36.63M ▼ |
| Q3-2024 | $-40.56M | $-34.14M | $19.88M | $1.32M | $-12.94M | $-34.14M |
CEO
Nadim Ahmed
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 120
Ratings Snapshot
Rating : B-
Most Recent Analyst Grades
Grade Summary
Showing Top 6 of 6
Price Target
Institutional Ownership
BIOIMPACT CAPITAL LLC
Shares:7.65M
Value:$83.14M
LYNX1 CAPITAL MANAGEMENT LP
Shares:5.77M
Value:$62.68M
BVF INC/IL
Shares:5.75M
Value:$62.51M
Summary
Showing Top 3 of 160